Certoparin
- Generic Name
- Certoparin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- V72OT3K19I
- Background
Certoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa. It is normally used to prevent deep venous thrombosis.
- Indication
Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.
- Associated Conditions
- Deep Vein Thrombosis, Thrombotic events caused by General Surgery, Thrombotic events caused by Mobility decreased, Thrombotic events caused by Stroke, Ischemic
- Associated Therapies
- -
Certoparin in Renal Patients Undergoing Hemodialysis
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 109
- Registration Number
- NCT01179620
- Locations
- 🇩🇪
Novartis Investigative Site Magdeburg, Magdeburg, Germany
🇩🇪Novartis Investigative Site Flensburg, Flensburg, Germany
🇩🇪Novartis Investigative Site Kronach, Kronach, Germany
A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3254
- Registration Number
- NCT00451412
- Locations
- 🇩🇪
Novartis investigative sites, Nürnberg, Germany
Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 342
- Registration Number
- NCT00311753
- Locations
- 🇨ðŸ‡
Novartis Pharmaceuticals, Basel, Switzerland
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00171769
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.